2025 Access to Medicines PharmD Internship & Fellowship Program
Calla Lily Clinical Care, Med Aditus, Roivant Sciences, and Roivant Social Ventures (RSV), have partnered to create summer internship opportunities to provide real-world drug development experience to talented PharmD students. The intentions of this program are to expand access to medicines to vulnerable populations, and to further UNC Eshelman School of Pharmacy's goal of providing future industry leaders with pharmaceutical experience during their PharmD tenure.
Reflecting on her experience Mackenzie Greene, RSV 2024 Global Access Fellow shared, “This fellowship pushed me out of my comfort zone, allowing me to further develop my leadership skills and adaptability, while growing my confidence as a future pharmacist. Working closely with the community we served in Rwanda has equipped me with a refined skillset, enabling me to navigate unique challenges, deliver high-quality equitable care, and advocate effectively for future patients facing barriers to healthcare access. I am deeply thankful for this opportunity, which has been a life-changing experience from start to finish."
We congratulate the following PharmD students on their 2025 internships and fellowships:
Naomi Aduroja, RSV Global Access Fellow volunteering with Cally Lily Clinical Care in London, England. Calla Lily is transforming drug delivery for women through the development of their novel vaginal platform technology that supports fertility, pregnancy, and other gynaecological conditions.
Ani Kalathil, Research and Development Intern on Roivant Sciences' Regulatory Affairs and Drug Safety team.
Rawan Morsy, RSV Global Access Fellow volunteering with Med Aditus in North Carolina and Kenya, Africa. Med Aditus is building access to affordable, high-quality medicines for underserved communities across Sub-Saharan Africa through addressing structural barriers in the regional healthcare landscape with sustainable, locally anchored solutions.
Ana Tan, Research and Development Intern on Roivant Sciences' Chemistry, Manufacturing, and Controls team.
Hunter Zell, RSV Global Access Fellow volunteering with Med Aditus in North Carolina and Kenya, Africa.
During the Spring 2025 semester all interns completed RSV's "Making Medicines" course, described in more detail below.
Roivant Social Ventures "Making Medicines" Course at the UNC Eshelman School of Pharmacy
During the Spring 2025 semester the 2025 Access to Medicines PharmD Interns and Fellows all completed "Making Medicines" at the UNC Eshelman School of Pharmacy, the top ranked School of Pharmacy in the United States. This innovative course was designed to introduce PharmD students to the new drug approval process and key issues in drug discovery, pre-clinical testing, clinical trials, FDA approval, and global access to medicines.
We would like to send a gracious thank you to our expert guest lecturers:
John Cox, CEO of Dyne Therapeutics, Executive Chairman of Minovia Therapeutics, and Member of the Board of Directors at Canopy Immunotherapeutics
Anuj Hasija, President of Double Filtered, Member of the Board of Directors at Arbutus Biopharma, and Former VP of Global Marketing at Novartis Oncology
Paul Mudd, Chief Development Officer of Priovant Therapeutics
Dan Patterson, VP & Head of CMC, Biologics & Gene Therapies at Roivant Sciences, and RSV Board Member
Steve Piscitelli, PharmD, VP and Head of Clinical Development at Dermavant
Clifford Samuel, Principal at PCMS1 Consulting, Fellow at the Berkman Klein Center for Internet & Society at Harvard University, Former SVP of Access Operations & Emerging Markets at Gilead Sciences, and RSV Advisory Board Member
Woody Sherman, Founder and CEO of Psivant
Elizabeth Wood, Chief Executive Officer of JURA Bio
It was a pleasure having these dynamic professionals share their real-world insights to inspire the next generation of PharmD leaders!